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cidence of acute toxic effects of the conditioning regimen (Maris et
al 2001) but require a greater patient and family participation in the
direct care. Many transplant centers plan to have all or part of the
care provided in the outpatient setting and need the support of
families and friends as caregivers. Much of the printed education
materials available to transplant patients is directed to ablative
transplants and can be misleading to patients and families. The
Allogeneic Patient Handbook at Duke Adult Stem Cell Transplant
(ASCT) Program contains patient instructions for high dose abla-
tive transplants.
Duke University Medical Center performed 36 non-myeloabla-
tive transplants in ﬁscal year 2003. Only 22% of these patients were
admitted to the hospital. The majority of the patients received all
of their care in the Adult Outpatient Clinic and at home with
assistance from home care services and family caregivers. A new set
of teaching guidelines, materials and methods need to be developed
in order to meet the changing education needs of transplant pa-
tients.
Prior to developing new materials and processes, the non-my-
eloablative transplant patients were surveyed by the ASCT pro-
gram nursing staff to determine how the current handbooks met
the educational needs and what opportunities did we have to
improve the content and the process. Patient satisfaction surveys
were also used to determine patient satisfaction with the educa-
tional process.
The Non-myeloablative Patient Handbook was written and re-
viewed by the Adult BMT Clinical Staff and approved by the Duke
Oncology Patient Education Committee.
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IMPLEMENTING BROVIAC CATHETER USE IN PHOTOPHERESIS FOR
CHRONIC GVHD IN PEDIATRIC HSCT PATIENTS
Fisher, V.L., Jekutis, B., Smucker, T. Rainbow Babies and Children’s
Hospital/Ireland Cancer Center, Cleveland, OH
The use of photophersis in the treatment of chronic GVHD has
been well documented in the adult HSCT patient population.
However, the use of photophersis in the pediatric HSCT patient
remains a formidable challenge, due to central access issues. May
institutions require pheresis catheter placement for photopheresis.
We report a series of 142 successful photopheresis sessions in ﬁve
pediatric patients utilizing a double lumen broviac catheter. All of
the patients had malignacies (2 ALL and 3 AML) The patients
ranged in age from 8-15 years and with weights of 20.1 kg to 58 kg
respectively. The number of photopheresis sessions for the patients
ranged from 8 to 52. The ECP procedure was performed using the
UVAR XTS photopheresis system (Therakos, West Chester, Pa)
as previously described. The mean treatment time for each pho-
topheresis procedure was 3.5 hours. The ﬂow rate during each
photophersis procedure averaged 10-12 ml/minute. Only one of
the ﬁve patients experienced hypovolemia as an adverse event,
successfully treated with ﬂuid replacement. There were no other
adverse events related to photopheresis. The use of tPA was re-
quired occasionally prior to the start of the procedure. We con-
clude that the use of a broviac catheter is a safe and practical
alternative to apheresis catheters for management of chronic
GVHD in pediatric HSCT patients.
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HEALTH-RELATED QUALITY OF LIFE AND SYMPTOM DISTRESS IN
PATIENTS PRIOR TO ALLOGENEIC STEM CELL TRANSPLANT
Bevans, M.1, Marden, S.1, Mayberry, H.1, Cusack, G.1, Soeken, K.2,
Kline Leidy, N.3 1. National Institutes of Health, Clinical Center,
Nursing and Patient Care Services, Bethesda, MD; 2. University of
Maryland, Baltimore, MD; 3. MEDTAP International, Bethesda, MD
Objective: This study examined health-related quality of life
(HRQL) and symptom distress (SD) in patients preparing to un-
dergo allogeneic stem-cell transplant (A-SCT) for the treatment of
hematological diseases. Methods: Prospective survey of patients
enrolled in an A-SCT clinical trial. HRQL was measured by the
physical (PCS) and mental (MCS) health scores of the Short
Form-36 (norm  50) and the Functional Assessment of Cancer
Therapy-General (FACT-G; range 0-100). SD was measured by
the Symptom Distress Scale (SDS; range 13-65). Patients com-
pleted the questionnaires in English or Spanish via a touch-screen
computer during the trial baseline period. Scores were compared
to published references for the 1998 general United States (US)
population (GP) and a cancer population (CP) using one sample
t-tests. Scores were also grouped by gender and compared to the
male/female GP using one sample t-tests. A p-value 0.05 was
considered signiﬁcant. Findings: Patients (N  76) were mostly
male (67%), ranging in age from 18-71 years (M  40; SD  14),
and either Caucasian (46%) or Hispanic (30%). Most (97%) had
ECOG 1. Baseline results demonstrated mean PCS and MCS
scores of pre-A-SCT patients were signiﬁcantly lower than the GP
(norm 50 vs. 43, p 0.001 and 47, p 0.015, respectively). The
mean PCS score for male patients was signiﬁcantly lower than male
GP (norm  51 vs. 42; p  0.001); mean MCS score did not differ
(norm  51 vs. 49; p  0.20). For female patients, the mean MCS
score was signiﬁcantly lower than female GP (norm  50 vs. 43;
p  .017); mean PCS score did not differ (norm 49 vs. 44; p 
0.05). FACT-G total score was signiﬁcantly lower than patients
with Hodgkin’s Disease (59 vs. 66; p  0.001). SDS scores (76%)
indicated low SD (25); 24% indicated moderate distress (range
25-32). Conclusion: Patients with hematological diseases, ECOG
1, prior to A-SCT have poorer HRQL compared to the US GP
and a cancer population, with relatively low levels of SD. Men
report more concerns related to physical health compared to men
in the GP. Women report more concerns related to mental health
compared to women in the GP.
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CONTINUOUS PLATELET DRIP: A UNIQUE APPROACH IN THE TREAT-
MENT OF SEVERE/REFRACTORY THROMBOCYTOPENIA IN THE PEDI-
ATRIC STEM CELL TRANSPLANT POPULATION
Talbert, G.1,2, Zbylut, C.1, Chelf, K.1, Frey, M.A.1,2, Martin, P.2,
Kurtzberg, J.2 1. The Duke University Children’s Hospital, Durham,
NC; 2. The Pediatric Stem Cell Transplant Program at Duke Univer-
sity, Durham, NC
Thrombocytopenia is an expected complication of marrow abla-
tive therapy. Platelets are the last hematopoietic cell to ablate and
the last to recover after conditioning for tranplant. Bleeding re-
mains a signiﬁcant cause of morbidity and morality in the im-
munosuppressed patients. Patients undergoing stem cell transplan-
tation are at greater risk due to the prolonged duration and severe
nature of the aplastic period. Therefore, long term supportive care
via platelet transfusion is a common and expected therapy in this
patient population. As a result of therapy, many patients become
refractory to platelet transfusions. These patients may require
more intensive measures that include frequent platelet transfusions
or continuous platelet drips to prevent complications from bleed-
ing. To further complicate matters, many patients undergoing
transplantation are often ﬂuid sensitive and at times ﬂuid re-
stricted. The added volume of multiple platelet transfusions can
pose additional risk to an already fragile patient. The use of
continuous platelet drips has proven to be an effective way to treat
severe/refractory thrombocytopenia and minimize the additional
ﬂuid volume. The Duke Pediatric Stem Cell Transplant Unit
utilizes continuous platelet drips for select patients. Patients re-
ceiving this therapy must meet speciﬁc criteria including throm-
Table. Patient Demographics
Age Sex Diagnosis HSCT Source GVHD
10 F ALL CR3 MUD-PB (6/6) Extensive
13 M ALL CR2 MUD-BM (6/6) Extensive
15 F AML CR2 MRD-PB (5/6) Extensive
15 M AML CR1 MRD-BM (5/6) Extensive
8 M AML CR3 UCB (4/6) Extensive
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